Advancements in Lower Extremity Deep Vein Thrombosis Researchfor Pancreatic Cancer
DOI:
https://doi.org/10.71321/38mrm773Keywords:
Pancreatic cancer, lower extremity deep vein thrombosis, risk factors, anticoagulant therapy, research progressAbstract
Pancreatic cancer demonstrates the greatest prevalence of thrombosis linked to malignancy in solid tumors, accompanied by a markedly heightened risk of venous thromboembolism (VTE). Early occurrence of VTE in cancer serves as a crucial predictor of adverse prognosis, jeopardizing patient survival and quality of life. The hypercoagulable condition triggered by the tumor microenvironment, integrated with host genetic predisposition and treatment-associated hazards, collaboratively escalates VTE susceptibility. This review methodically outlines the pathophysiology and elevated risk elements for lower extremity deep vein thrombosis (DVT) in pancreatic cancer, while appraising the efficacy of present preventive approaches, seeking to establish a theoretical groundwork for refining clinical management.
References
[1] Siegel, RL, Miller, KD, Wagle, NS, and Jemal, A. Cancer statistics, 2023. CA: a cancer journal for clinicians. 2023;73(1):17-48. https://doi.org/10.3322/caac.21763
[2] Costamagna, G, Navi, BB, Beyeler, M, Hottinger, AF, Alberio, L, and Michel, P. Ischemic Stroke in Cancer: Mechanisms, Biomarkers, and Implications for Treatment. Seminars in thrombosis and hemostasis. 2024;50(3):342-59. https://doi.org/10.1055/s-0043-1771270
[3] Kothari, A, and Flick, MJ. Coagulation Signaling through PAR1 as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma. International journal of molecular sciences. 2021;22(10). https://doi.org/10.3390/ijms22105138
[4] Glassman, D, Bateman, NW, Lee, S, Zhao, L, Yao, J, Tan, Y, et al. Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer. Cancers. 2022;14(6). https://doi.org/10.3390/cancers14061496
[5] Gyldenholm, T, and Larsen, JB. Cancer-Associated Thrombosis and Beyond: Biomarkers, Treatments, and Cancer-Hemostasis Interactions. Seminars in thrombosis and hemostasis. 2024;50(3):325-7. https://doi.org/10.1055/s-0043-1778104
[6] Frere, C, Bournet, B, Gourgou, S, Fraisse, J, Canivet, C, Connors, JM, et al. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Gastroenterology. 2020;158(5):1346-58.e4. https://doi.org/10.1053/j.gastro.2019.12.009
[7] Sharma, BK, Flick, MJ, and Palumbo, JS. Cancer-Associated Thrombosis: A Two-Way Street. Seminars in thrombosis and hemostasis. 2019;45(6):559-68. https://doi.org/10.1055/s-0039-1693472
[8] Falanga, A, and Marchetti, M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. Journal of thrombosis and haemostasis : JTH. 2023;21(6):1397-408. https://doi.org/10.1016/j.jtha.2023.02.029
[9] Robbins, KJ, Newcomer, KF, Jr., Barnell, EK, Anzelmo, MA, Liu, J, and Hawkins, WG. Neoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis. Annals of surgical oncology. 2024;31(5):2873-81. https://doi.org/10.1245/s10434-023-14763-y
[10] Liz-Pimenta, J, Tavares, V, Neto, BV, Santos, JMO, Guedes, CB, Araújo, A, et al. Thrombosis and cachexia in cancer: Two partners in crime? Critical reviews in oncology/hematology. 2023;186:103989. https://doi.org/10.1016/j.critrevonc.2023.103989
[11] Tavares, V, Pinto, R, Assis, J, Pereira, D, and Medeiros, R. Venous thromboembolism GWAS reported genetic makeup and the hallmarks of cancer: Linkage to ovarian tumour behaviour. Biochimica et biophysica acta Reviews on cancer. 2020;1873(1):188331. https://doi.org/10.1016/j.bbcan.2019.188331
[12] Hanna-Sawires, RG, Groen, JV, Hamming, A, Tollenaar, R, Mesker, WE, Luelmo, SAC, et al. Incidence, timing and risk factors of venous thromboembolic events in patients with pancreatic cancer. Thrombosis research. 2021;207:134-9. https://doi.org/10.1016/j.thromres.2021.08.002
[13] Tavares, V, Neto, BV, Vilas-Boas, MI, Pereira, D, and Medeiros, R. Impact of hereditary thrombophilia on cancer-associated thrombosis, tumour susceptibility and progression: A review of existing evidence. Biochimica et biophysica acta Reviews on cancer. 2022;1877(5):188778. https://doi.org/10.1016/j.bbcan.2022.188778
[14] Fernandes, CJ, Morinaga, LTK, Alves, JLJ, Castro, MA, Calderaro, D, Jardim, CVP, et al. Cancer-associated thrombosis: the when, how and why. European respiratory review : an official journal of the European Respiratory Society. 2019;28(151). https://doi.org/10.1183/16000617.0119-2018
[15] Jiang, S, Li, H, Zhang, L, Mu, W, Zhang, Y, Chen, T, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic acids research. 2025;53(D1):D1670-d6. https://doi.org/10.1093/nar/gkae973
[16] Eshmuminov, D, Aminjonov, B, Palm, RF, Malleo, G, Schmocker, RK, Abdallah, R, et al. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Annals of surgical oncology. 2023;30(7):4417-28. https://doi.org/10.1245/s10434-023-13353-2
[17] Demers, M, and Wagner, DD. Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology. 2013;2(2):e22946. https://doi.org/10.4161/onci.22946
[18] Demers, M, Wong, SL, Martinod, K, Gallant, M, Cabral, JE, Wang, Y, et al. Priming of neutrophils toward NETosis promotes tumor growth. Oncoimmunology. 2016;5(5):e1134073. https://doi.org/10.1080/2162402x.2015.1134073
[19] Oto, J, Navarro, S, Larsen, AC, Solmoirago, MJ, Plana, E, Hervás, D, et al. MicroRNAs and Neutrophil Activation Markers Predict Venous Thrombosis in Pancreatic Ductal Adenocarcinoma and Distal Extrahepatic Cholangiocarcinoma. International journal of molecular sciences. 2020;21(3). https://doi.org/10.3390/ijms21030840
[20] Riedl, J, Pabinger, I, and Ay, C. Platelets in cancer and thrombosis. Hamostaseologie. 2014;34(1):54-62. https://doi.org/10.5482/hamo-13-10-0054
[21] Willems, RAL, Konings, J, Huskens, D, Middelveld, H, Pepels-Aarts, N, Verbeet, L, et al. Altered whole blood thrombin generation and hyperresponsive platelets in patients with pancreatic cancer. Journal of thrombosis and haemostasis : JTH. 2024;22(4):1132-44. https://doi.org/10.1016/j.jtha.2023.12.037
[22] Poruk, KE, Firpo, MA, Huerter, LM, Scaife, CL, Emerson, LL, Boucher, KM, et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(10):2605-10. https://doi.org/10.1158/1055-9965.Epi-10-0178
[23] Merten, M, and Thiagarajan, P. P-selectin expression on platelets determines size and stability of platelet aggregates. Circulation. 2000;102(16):1931-6. https://doi.org/10.1161/01.cir.102.16.1931
[24] Moik, F, Prager, G, Thaler, J, Posch, F, Wiedemann, S, Schramm, T, et al. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer. Arteriosclerosis, thrombosis, and vascular biology. 2021;41(11):2837-47. https://doi.org/10.1161/atvbaha.121.316463
[25] Bosch, FTM, Campello, E, Mulder, FI, Ilich, A, Henderson, MW, Prokopenko, Y, et al. Contact system and intrinsic pathway activation in patients with advanced pancreatic cancer: a prospective cohort study. Journal of thrombosis and haemostasis : JTH. 2023;21(10):2863-72. https://doi.org/10.1016/j.jtha.2023.06.009
[26] Herre, M, Cedervall, J, Mackman, N, and Olsson, AK. Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases. Physiological reviews. 2023;103(1):277-312. https://doi.org/10.1152/physrev.00062.2021
[27] Grover, SP, and Mackman, N. Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 2018;38(4):709-25. https://doi.org/10.1161/atvbaha.117.309846
[28] Coumans, FAW, Brisson, AR, Buzas, EI, Dignat-George, F, Drees, EEE, El-Andaloussi, S, et al. Methodological Guidelines to Study Extracellular Vesicles. Circulation research. 2017;120(10):1632-48. https://doi.org/10.1161/circresaha.117.309417
[29] Kasthuri, RS, Hisada, Y, Ilich, A, Key, NS, and Mackman, N. Effect of chemotherapy and longitudinal analysis of circulating extracellular vesicle tissue factor activity in patients with pancreatic and colorectal cancer. Research and practice in thrombosis and haemostasis. 2020;4(4):636-43. https://doi.org/10.1002/rth2.12317
[30] Thomas, GM, Brill, A, Mezouar, S, Crescence, L, Gallant, M, Dubois, C, et al. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. Journal of thrombosis and haemostasis : JTH. 2015;13(7):1310-9. https://doi.org/10.1111/jth.13002
[31] Kaur, S, Kumar, S, Momi, N, Sasson, AR, and Batra, SK. Mucins in pancreatic cancer and its microenvironment. Nature reviews Gastroenterology & hepatology. 2013;10(10):607-20. https://doi.org/10.1038/nrgastro.2013.120
[32] Pilli, VS, Datta, A, Dorsey, A, Liu, B, and Majumder, R. Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation. Oncology reports. 2020;44(4):1322-32. https://doi.org/10.3892/or.2020.7689
[33] Gierula, M, and Ahnström, J. Anticoagulant protein S-New insights on interactions and functions. Journal of thrombosis and haemostasis : JTH. 2020;18(11):2801-11. https://doi.org/10.1111/jth.15025
[34] Pilli, VS, Datta, A, Afreen, S, Catalano, D, Szabo, G, and Majumder, R. Hypoxia downregulates protein S expression. Blood. 2018;132(4):452-5. https://doi.org/10.1182/blood-2018-04-841585
[35] Frere, C. Burden of venous thromboembolism in patients with pancreatic cancer. World journal of gastroenterology. 2021;27(19):2325-40. https://doi.org/10.3748/wjg.v27.i19.2325
[36] Yamai, T, Ikezawa, K, Hiraga, E, Kawamoto, Y, Hirao, T, Higashi, S, et al. Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel. PloS one. 2022;17(3):e0264653. https://doi.org/10.1371/journal.pone.0264653
[37] Carrier, M, Abou-Nassar, K, Mallick, R, Tagalakis, V, Shivakumar, S, Schattner, A, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. The New England journal of medicine. 2019;380(8):711-9. https://doi.org/10.1056/NEJMoa1814468
[38] Mantha, S, Laube, E, Miao, Y, Sarasohn, DM, Parameswaran, R, Stefanik, S, et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. Journal of thrombosis and thrombolysis. 2017;43(2):166-71. https://doi.org/10.1007/s11239-016-1429-1
[39] Karampinis, I, Nowak, K, Koett, J, Mess, C, Wagner, L, Gaiser, T, et al. Von Willebrand factor in the plasma and in the tumor tissue predicts cancer-associated thrombosis and mortality. Haematologica. 2023;108(1):261-6. https://doi.org/10.3324/haematol.2022.281315
[40] Woei, AJFJ, Tesselaar, ME, Garcia Rodriguez, P, Romijn, FP, Bertina, RM, and Osanto, S. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? British journal of cancer. 2016;115(3):332-8. https://doi.org/10.1038/bjc.2016.170
[41] Simanek, R, Vormittag, R, Ay, C, Alguel, G, Dunkler, D, Schwarzinger, I, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Journal of thrombosis and haemostasis : JTH. 2010;8(1):114-20. https://doi.org/10.1111/j.1538-7836.2009.03680.x
[42] Wei, Z, Zhang, Z, Ye, B, Luo, Z, Zeng, L, and Zhou, J. Single-cell Sequencing and Multi-omics Integration Reveals a Lipid Metabolism-Based Prognostic Model for 5-Fluorouracil Resistance in Breast Cancer. Cell Conflux [Internet]. 2025 May 14 [cited 2026 Mar 10];1:e173. Available from: https://ojs.lifeconfluxpress.com/index.php/cellconflux/article/view/xdm8ef82
[43] Ueno, H, Ikeda, M, Ueno, M, Mizuno, N, Ioka, T, Omuro, Y, et al. Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer chemotherapy and pharmacology. 2016;77(3):595-603. https://doi.org/10.1007/s00280-016-2972-3
[44] Farge, D, Debourdeau, P, Beckers, M, Baglin, C, Bauersachs, RM, Brenner, B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of thrombosis and haemostasis : JTH. 2013;11(1):56-70. https://doi.org/10.1111/jth.12070
[45] Becattini, C, Pace, U, Pirozzi, F, Donini, A, Avruscio, G, Rondelli, F, et al. Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Blood. 2022;140(8):900-8. https://doi.org/10.1182/blood.2022015796
[46] Pelzer, U, Opitz, B, Deutschinoff, G, Stauch, M, Reitzig, PC, Hahnfeld, S, et al. Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33(18):2028-34. https://doi.org/10.1200/jco.2014.55.1481
[47] Frere, C, Wahl, C, Rueda-Camino, JA, Crichi, B, Prata, PH, Marjanovic, Z, et al. A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. Best practice & research Clinical haematology. 2022;35(1):101348. https://doi.org/10.1016/j.beha.2022.101348
[48] Philip, PA, Lacy, J, Portales, F, Sobrero, A, Pazo-Cid, R, Manzano Mozo, JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. The lancet Gastroenterology & hepatology. 2020;5(3):285-94. https://doi.org/10.1016/s2468-1253(19)30327-9
[49] Aguilera Munoz, L, de Mestier, L, Lamallem, H, Jaïs, B, Maire, F, Lévy, P, et al. Gastrointestinal bleeding in patients with pancreatic cancer: Causes and haemostatic treatments. United European gastroenterology journal. 2020;8(9):1106-14. https://doi.org/10.1177/2050640620939788
[50] Tran, E, and Ledbetter, LE. A retrospective evaluation of direct oral anticoagulant (DOAC) management strategies in patients with cancer on active chemotherapy. Journal of thrombosis and thrombolysis. 2023;55(4):721-8. https://doi.org/10.1007/s11239-023-02778-x
[51] Groen, JV, Stommel, MWJ, Sarasqueta, AF, Besselink, MG, Brosens, LAA, van Eijck, CHJ, et al. Surgical management and pathological assessment of pancreatoduodenectomy with venous resection: an international survey among surgeons and pathologists. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2021;23(1):80-9. https://doi.org/10.1016/j.hpb.2020.04.015
[52] Clancy, TE, Baker, EH, Maegawa, FA, Raoof, M, Winslow, E, and House, MG. AHPBA guidelines for managing VTE prophylaxis and anticoagulation for pancreatic surgery. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2022;24(5):575-85. https://doi.org/10.1016/j.hpb.2021.12.010
[53] Sood, D, Kuchta, K, Paterakos, P, Schwarz, JL, Rojas, A, Choi, SH, et al. Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. Journal of surgical oncology. 2023;127(3):413-25. https://doi.org/10.1002/jso.27135
Type
Published
Data Availability Statement
All data required to evaluate the conclusions of this paper are included in the manuscript or supplementary materials. Additional data related to this article may be made available from the authors upon reasonable request.
Issue
Section
License
Copyright (c) 2026 Cell Conflux
This work is licensed under a Creative Commons Attribution 4.0 International License.
